Pscilly

Reviews of LPH-5 – Selective small-molecule 5-HT2A agonist

No reviews yet. Share the first one.

LPH-5 – Selective small-molecule 5-HT2A agonist by Lophora ApS

Investigational candidate being developed for depressive disorders and other mood and anxiety disorders. Its Phase I single-ascending-dose study is complete, and topline results were reported in June 2026. Investigational; not…

Guides about LPH-5 – Selective small-molecule 5-HT2A agonist

Related news

More from Lophora ApS